The New Math Of Fuel Value: Why Smart Drivers Look Beyond Pump Price

Caltex puts engine cleanliness, fuel quality, and dependable performance at the center of its approach to helping drivers maximize every refill.

What’s In Store At Noel Bazaar 2026: A Modern Paskong Pinoy Experience

Noel Bazaar 2026 brings together holiday shopping, Filipino Christmas traditions, live performances, and family activities across two venues.

From Access To Agency: How Tala’s Philippine Experience Is Shaping Its ASEAN Vision

Tala is using nearly a decade of experience in the Philippines to shape its broader vision for responsible credit access across ASEAN.

Nestlé Group CEO Underscores The Strategic Importance Of The Philippines To The Company’s Growth

Nestlé Group CEO Philipp Navratil highlights the Philippines as one of the company’s most important growth markets worldwide.

Lagundi Helps In Covid Patients Recovery, Study Shows

Lagundi has contributed to the recovery of patients with mild symptoms of Covid-19, DOST Secretary Fortunato de la Peña said.

Lagundi Helps In Covid Patients Recovery, Study Shows

66
66

How do you feel about this story?

Express Your Reaction
Like
Love
Haha
Wow
Sad
Angry

Department of Science and Technology (DOST) Secretary Fortunato de la Peña on Wednesday said that based on clinical trial, lagundi has contributed to the recovery of patients with mild symptoms of coronavirus disease 2019 (Covid-19).

The DOST-supported clinical trial involved 278 patients from seven quarantine facilities. Half of them received lagundi as an adjuvant therapy.

“All of them have recovered. But those who received lagundi gained back their sense of smell faster,” he said in a public briefing.

The clinical trial aims to determine if lagundi can decrease the number of patients who progress from mild to moderate or severe cases. Loss of smell is among the apparent symptoms of Covid-19.

De la Peña believes that because of lagundi’s pharmacologic properties, it could be a suitable choice for the symptomatic treatment of Covid-19 patients.

While those who were given lagundi became free from the symptoms faster, de la Peña acknowledged that both groups had an average of eight days to recover.

“There is no significant difference in time to recovery between those who took lagundi and the other group. In terms of safety, no serious adverse events were reported,” he said.

De la Peña earlier said that no participant has progressed to moderate or severe Covid-19.

Meanwhile, he said researchers will be finalizing if lagundi have reduced the viral load in the participants’ blood.

If they get good results, he said they are expecting that the same clinical trial can be pursued among patients with moderate symptoms. (PNA)